Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 3Neoplasms 3Glioblastoma 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Solid Tumors 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma 1Neuroectodermal Tumors 1Nervous System Diseases 1Neoplasms by Site 1Neoplasms by Histologic Type 1Head and Neck Neoplasms 1HER2-negative Breast Cancer 1Gliosarcoma 1For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment 1Esophageal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Astrocytoma 1Advanced Malignant Solid Neoplasm 1Advanced Malignancies 1

Interventions

parsaclisib 2MLN 8237 2zanidatamab 1tislelizumab 1tanespimycin 1spartalizumab 1sitravatinib 1pembrolizumab 1pamiparib 1liposomal doxorubicin 1lenvatinib 1epothilone B 1cabiralizumab 1Temozolomide 1Nivolumab 1N-alpha-(2,4,6-triisopropyl-phenylsulfonyl)-3-amidino-(L)-phenyl-alanine-4-ethoxycarbonyl-piperazide hydrochloride 1HMPL-013 1Capecitabine 1AZD7648 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Malignancies × pamiparib × Clear all
NCT04164199 2026-06-03

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

BeOne Medicines

Phase 3 Completed
404 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡